顺铂对鼻咽癌细胞NKG2D配体表达和NK细胞杀伤活性的增强作用

doi:10.3971/j.issn.1000-8578.2009.12.002

顺铂对鼻咽癌细胞NKG2D配体表达和NK细胞杀伤活性的增强作用

Cisplatin Induces Up-regulation of NKG2D Ligands and Enhances Natural Killer Cell Lysis of Nasopharyngeal Carcinoma Cells

摘要

摘要: 目的研究顺铂(Cisplatin, DDP)作用前后人鼻咽癌细胞CNE2 NKG2D配体和HLA-Ⅰ类分子表达的改变及NK细胞杀伤活性的变化。方法 MTT法测定DDP对CNE2细胞的50%抑制量（IC₅₀）；以此浓度DDP作用CNE2细胞24h，乳酸脱氢酶释放法检测效靶比20∶1时，NK细胞对DDP作用前后的CNE2细胞的杀伤活性；流式细胞仪检测DDP作用前后的CNE2细胞表面NKG2D配体(MICA/B、ULBP1、ULBP2、ULBP3)和HLA-Ⅰ类分子表达的变化。结果 DDP对CNE2细胞的IC₅₀为5mg/L。效靶比20∶1时，NK细胞对5mg/L DDP作用前后的CNE2细胞的杀伤活性分别为（38.11±1.41）%，（47.71±1.53）%，差异有统计学意义（P＜0.05），DDP作用后CNE2细胞表面MICA/B、ULBP1、ULBP3表达显著升高，与作用前相比差异有统计学意义（P＜0.05）。ULBP2、HLA-Ⅰ类分子无明显变化(P＞0.05)。结论 DDP能提高CNE2细胞NKG2D配体(MICA/B、ULBP1、ULBP3)的表达，从而增强CNE2细胞对NK细胞杀伤的敏感度。

Abstract: Objective To explore the effects of Cisplatin(DDP) on the expression of NKG2D ligands and HLA-class Ⅰ molecules on human nasopharyngeal carcinoma cell line (CNE2) and natural killer (NK)cells cytotoxicity. Methods The IC₅₀ of DDP against CNE2 cells were measured by MTT assay. Cytotoxicities of NK cells isolated from 3 healthy volunteers against CNE2 cells before and after cultured by DDP were analyzed by LDH releasing assay at effector-to-target cell ratio(E∶T) of 20∶1. The expression of NKG2D ligands(MICA/B, ULBP1, ULBP2, ULBP3), HLA-classⅠmolecules before and after treated by DDP were assayed by flow cytometery. Results DDP could decrease the proliferation and survival rate of CNE2 cells. The IC₅₀ was 5mg/L. The cytotoxicity of NK cells against CNE2 cells cultured by DDP was significantly enhanced. The expression of NKG2D ligands(MICA/B, ULBP1, ULBP3) of CNE2 cells were up-expressed after cultured with DDP. There were no significant difference of expression of ULBP2 and HLA-classⅠmolecules before and after treated by DDP(P>0.05). Conclusion The results indicate that DDP up-regulated the expressions of MICA/B, ULBP-1, ULBP-3, which enhanced the susceptibility of CNE2 cells to natural killer cell-mediated lysis.

HTML全文

参考文献(0)

施引文献

资源附件(0)